Greetings!
Chris:
I do have an interest in this area as well, however, my interests may be a
bit different. My interests are in how one can apply what is being learned
about pharmacogenetics, pharmacogenomics and proteomics to the development
of new diagnostic physiologic imaging radiopharmaceuticals and therapeutic
radiopharmaceuticals for use in nuclear medicine. I am also interested in
how existing and new diagnostic radiopharmaceuticals may be used to assess
efficacy and monitor the distribution, metabolism, excretion etc. of new
pharmaceuticals developed as a result of advances in pharmacogenetics,
pharmacogenomics and proteomics. Here at Duke, we also have a positron
emission tomography (P.E.T.) imaging center, so this adds another level of
technology to what may be possible to detect and enhance the effective
treatment of disease, especially cancers in the future. If you should have
some interest or if you know anyone with interests in this potential area
of application, I would welcome the opportunity to communicate further in
this regard.
Now for the reason I am replying to your posting. I recently attended a
symposium entitled "Pharmacogenetics 2001: Drug Development in a
Genetically Informed Environment" which had several outstanding speakers.
One came to mind while reading your posting. You may want to look into the
work that William E. Evans, PharmD is doing at St. Jude Children's Research
Hospital (http://www2.stjude.org/). He gave an excellent presentation
entitled "Pharmacogenomics: Translating Functional Genomics into Rational
Therapeutics." Also, you may want to go to http://www.ppdi.com/pgx2001 to
get some information on the symposium where Dr. Evans and others spoke. In
addition, you may find http://www.pgxsolutions.com to be of interest as
well.
Finally, you may want to consider contacting a colleague of mine, William
Petros, PharmD here at Duke. I recently learned Bill is one of the
scientists here involved in linking three previously identified genetic
variations to the length of survival in a group of patients with metastatic
breast cancer treated with high doses of anticancer agents. Sorry, I do
not have the citation for his publication at the moment but perhaps you
find this via literature search or by contacting Bill at
petro004@mc.duke.edu
Hope you find this information helpful,
Neil A. Petry, RPh, MS, BCNP, FAPhA
Assistant Professor of Radiology
Director, Radiopharmacy and Nuclear Medicine Laboratory
133 Bell Building, Box 3304
Duke University Medical Center
Durham, NC 27710
919-684-3773
919-684-1230 (Fax)
petry005@mc.duke.edu
Clinical Assistant Professor of Pharmacy Practice
School of Pharmacy, Campbell University
"Christopher Poole" <PooleCD@Cardiff.ac.uk>@pharmweb1.man.ac.uk> on
07/11/2001 08:12:16 AM
Please respond to "PharmCare" <PharmCare@pharmweb1.man.ac.uk>
Sent by: <PharmCare@pharmweb1.man.ac.uk>
To: "PharmCare" <PharmCare@pharmweb1.man.ac.uk>
cc:
Subject: Re: Pharmacogenomics in practice
Is anyone out there using pharmacogenomic profiling in routine
practice or developing pilot models of the same?
I would be grateful to hear from any contributor working in this field
as it is an applied research interest I am very keen to advance.
Regards,
Chris Poole
Postdoctoral Research Associate
Welsh School of Pharmacy Centre for Socioeconomic Research
Cardiff University
Redwood Building
King Edward VII Avenue
Cathays Park
CARDIFF CF10 3XF
Telephone: +44 (0)29 2087 6017
Mobile: +44 (0)7733 004258
e-mail: poolecd@cf.ac.uk
|